Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists · 2026
Prevalence and predictors of polypharmacy and psychotropic use among Australian Defence Force veterans transitioning from military to civilian life.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mellor Rebecca, Cronin Andrew, Raut Sanket B
Аннотация
BackgroundPolypharmacy is a growing concern among veterans due to high rates of multi-morbidity and its complex pharmacologic management. This study examined the prevalence and predictors of polypharmacy among Australian Defence Force (ADF) veterans transitioning from military to civilian life.MethodsA retrospective cohort analysis was conducted using electronic medical records from 1210 ADF veterans attending a medical service. General polypharmacy was defined as ≥5 medications, and psychotropic and other N-class polypharmacy as ≥2 medications within those classes. Multivariable logistic regression identified demographic and clinical predictors.ResultsGeneral polypharmacy occurred in 19.1% of veterans, psychotropic polypharmacy in 9.8% and other N-class polypharmacy in 14.6%. Veterans with post-traumatic stress disorder (PTSD) had significantly higher rates of psychotropic (25.9% vs 4.5%) and general polypharmacy (33.7% vs 14.4%) (p < .001). Psychiatric comorbidity burden was the strongest predictor of psychotropic polypharmacy (OR 1.91), while PTSD independently doubled the odds (OR 2.07). General polypharmacy was primarily associated with medical (OR 1.51) and psychiatric comorbidities (OR 1.41).ConclusionsPolypharmacy is common among Australian veterans transitioning from military to civilian life, particularly those with PTSD and multiple comorbidities, highlighting the need for early medication review and deprescribing strategies.